Form 8-K - Current report:
SEC Accession No. 0000950170-24-112962
Filing Date
2024-10-04
Accepted
2024-10-04 17:00:08
Documents
11
Period of Report
2024-10-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K omga-20241002.htm   iXBRL 8-K 47160
  Complete submission text file 0000950170-24-112962.txt   168909

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20241002.xsd EX-101.SCH 29130
13 EXTRACTED XBRL INSTANCE DOCUMENT omga-20241002_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 241355507
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)